You must be 21 years of age or older to enter Curo. Products and information on this site are intended for laboratory research use only and are not for human or animal use.
Research-use material
Metabolic & Performance$114
Save 17% | $24 offThis set includes one CJC-1295 no DAC compound and one Ipamorelin compound. Each compound is packaged separately and is not pre-mixed.
A GHRH-analog and selective-secretagogue pairing, studied together for a larger combined growth-hormone pulse than either compound produces alone.
For laboratory research use only. Not for human or animal consumption.
This set pairs CJC-1295 no DAC, a short-acting GHRH analog, with Ipamorelin, a selective growth-hormone secretagogue. The two ship as separate products and are not pre-mixed. They reach the pituitary through different receptors: CJC-1295 no DAC signals along the GHRH pathway, while Ipamorelin works through the ghrelin-receptor pathway. Research interest in combining them centers on that separation, since the two signals converge on the same growth-hormone-releasing cells from independent directions.
Because the pathways are distinct rather than overlapping, controlled studies of GHRH-plus-secretagogue pairings have generally reported a combined growth-hormone pulse greater than either compound produces on its own, though not every study has reproduced the effect. Research centers on growth-hormone and downstream IGF-1 signaling, with the short-acting GHRH component preserving a more pulse-style profile and the selective secretagogue adding a clean release without meaningfully raising cortisol or prolactin. It is commonly studied in growth-hormone-axis models and in recovery, sleep, and body-composition research.
Dedicated controlled data on this specific pairing remains limited, and much of the supporting evidence comes from earlier GHRH-and-secretagogue literature and from animal and laboratory work. That keeps both compounds investigational and distinct from approved therapies. Neither is FDA-approved.